Pozen (NASDAQ:POZN): POZEN announced that it filed for FDA approval of its proprietary, less gastro-erosive aspirin, causing Roth Capital to believe that the company will probably license the drug or carry out another corporate transaction during the year. The firm keeps its Buy rating and a $10 price target on the stock.
Never trust these pumpers they front run for henge funds. Also never buy but always sell into them useless press releases like yesterday by management. That was released to drum up sheep for management to sell to. In a few weeks you will see the filing that they were sellers again.